Controlled Release of a Protein Using a Ceramic Carrier and Zinc Ions as a Novel Approach to the Treatment of Osteoporosis

Abstract:

The release property of osteoprotegerin (OPG) from hydroxyapatite / chondroitin sulphate (HAp/ChS) microparticles was described in this paper. The formulation was conducted by subsequent addition of zinc chloride solution into the mixture of HAp/ChS microparticles as a ceramic carrier and OPG solution. The release of OPG from the microparticles in PBS was positively correlated with soaking time without initial burst. The release rate of OPG was decreased with the increase of the amounts of zinc cation, which was not dependent of ChS wt% in the microparticles. The controlled release of OPG would provide the improvement of drug effect and the reduction of adverse effects. These findings reveal further investigation of the other antiresortive agents as a potential safer medication for osteoporosis.

• Periodical: Key Engineering Materials (Volume 631)
• Pages: 332-337
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.631.332
• Online since: November 2014
• Authors: H. Watanabe, Toshiyuki Ikoma, M. Tanaka, T. Yoshioka, J. Tanaka
• Keywords: Chondroitin Sulfate, Controlled Release, Hydroxyapatite (HA), Osteoporosis, Osteoprotegerin, Zinc

References

[1] RANMARK (denosumab) [package insert]: Daiichi-Sankyo., (2012).

[2] M. Tanaka et al. 16th Annual meetng of the Japan osteoporosis society (2013).

[3] W. S. Simonet et al. Cell, 89 (1997) p.309–319.

[4] T. Matsumoto et al. Biomaterials 25 (2004) pp.3807-3812.

[5] Y. Mizushima et al. J. Controlled Release 110 (2006) pp.260-265.

[6] K. Surendrakumar et al. J. Controlled Release 91 (2003) p.385–394.

[7] W.E. Hennink et al. J. Controlled Release 48 (1997) p.107–114.

[8] V. Midy et al. J Biomed Mater Res. 41 (1998) p.405–411.

[8] Masatsugu Isobe et al. J Biomed Mater Res. 32 (1996) pp.433-438.

[9] Wei Xiao et al. Acta Biomaterialia 9 (2013) p.8374–8383.

[10] T. Ikoma et al. Key Eng. Mater. 288-289 (2005) pp.159-162.

[11] T. Ikoma et al. Transactions of the Mater. Research Society of Japan 29.

[6] (2004) pp.2911-2914.

[12] H. Watanabe et al. Key Eng. Mater. 309-311 (2005) pp.533-536.

[13] H. Watanabe et al. Key Eng. Mater. 330-332 (2006) pp.1009-1012.

[14] B.Y. Wang and F. Caruso, Adv. Mater. 18 (2006) pp.795-800.

[15] R. Shibsekhar et al. Biophysical Chemistry 119 (2006) pp.14-22.

[16] K. Ishihara et al. Biomaterial Science, Tokyo Kagaku Doujin (2003) p.133.

[17] Guthans, S. L., and Morgan, W. T. Arch Biochem. Biophys. 218, (1982) pp.320-328.

[18] Morgan, W. T. Biochemistry 20 (1981) p.1054–1061.

[19] Morgan, W. T. Biochemistry 24 (1985) p.1496–1501.

[20] Osteoprotegerin / TNFRSF11B / FcChimera Catalog Number: 805-OS/CF CARRIER-FREE, R & D systems.

[21] Steven M. Jay and W. Mark Saltzman J. Controlled Release February 20 134(1) (2009) pp.26-34.

[22] Gray CJ et al. Biotechnol. Bioeng. 31(6) (1988) pp.607-612.